重组白介素2与顺铂治疗恶性胸腹水的疗效观察  

Therapeutic evaluation of cisplation plus interleukin-Ⅱ in malignant hydrothorax and ascites

作　　者：袁云芳[1] 常爱琴[1] 王晓锦 

机构地区：[1]河南省肿瘤医院,河南郑州450008 [2]洛阳市第五人民医院,河南洛阳471000

出　　处：《河南医学研究》2000年第4期331-332,共2页Henan Medical Research

摘　　要：目的：观察重组白介素（ｒＩＬ－２）与顺铂（ＤＤＰ）胸腹腔注入治疗恶性胸腹水的疗效。方法：对４５例恶性胸腹水患者应用ｒＩＬ－２与ＤＤＰ胸腹腔注入；对照组４０例患者采用ＤＤＰ做胸腹腔注入以做比较。结果：治疗组治疗恶性胸腹水总有效率８９％，其中胸水有效率达９０％，腹水有效率达８８％。ＤＤＰ对照组治疗恶性胸腹水总有效率７０％，其中胸水有效率达７２．２％，腹水有效率达６８．２％。结论：ｒＩＬ－２与ＤＤＰ联合应用治疗恶性胸腹水有显著的协同作用（Ｘ２＝４．７２，Ｐ＜０．０５），毒副反应小，见效快，能及时减轻患者的痛苦，是安全有效的方法。Objective: To boserve therapeutic effectiveness of cisplatin plus interleukin-Ⅱ in malignant hydrothorax and ascites. Methos: In experimental group,45 cases were injected interleukin-Ⅱ and cisplation into thoracic cavity or abdominal cavity once a week,3-6 weeks as one cylce. As a control group,40 cases were injected cisplation alone in the same way. Results: The total effective rate in experimental group was 89%, about 90% in hydrothorax,89% in ascites. The lates in control group were 70%,72. 2% and 68. 2%, respectively. Conclusion: Interleukin-Ⅱ and cisplatin were synergistic in treating malignatn hydrothorax and ascites. Statistic management was significant(X2= 4.72 P < 0. 05 ). It has practical value of extending to clinical appliction.

关 键 词：重组白介素2 顺铂 恶性胸腹水 胸腹腔注入 

分 类 号：R561.305[医药卫生—呼吸系统] R730.5[医药卫生—内科学]